PS
ALNY icon

Principal Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Principal Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Sell
1,389
-1,356
-49% -$409K 0.01% 1161
2026
Q1 		$908K Buy
2,745
+119
+5% +$40.5K 0.01% 755
2025
Q4 		$1.04M Buy
2,626
+188
+8% +$83.2K 0.02% 683
2025
Q3 		$1.11M Buy
2,438
+724
+42% +$295K 0.02% 633
2025
Q2 		$559K Buy
1,714
+527
+44% +$146K 0.01% 814
2025
Q1 		$279K Hold
1,187
– – 0.01% 1008
2024
Q4 		$279K Buy
1,187
+1,066
+881% +$280K 0.01% 1004
2024
Q3 		$33.3K Buy
121
+6
+5% +$1.56K ﹤0.01% 1872
2024
Q2 		$27.9K Buy
115
+25
+28% +$3.95K ﹤0.01% 1891
2024
Q1 		$13.5K Sell
90
-12
-12% -$2K ﹤0.01% 2198
2023
Q4 		$19.5K Buy
+102
New +$17.4K ﹤0.01% 1929

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Securities's ALNY Position: Q2 2026 in Review

Principal Securities reduced its Alnylam Pharmaceuticals (ALNY) stake by 49% in Q2 2026, selling an estimated $409K and leaving 1,389 shares worth $418K. The position accounts for 0.01% of the portfolio, ranked #1161.

Principal Securities first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.11M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Principal Securities held 1,389 shares of Alnylam Pharmaceuticals worth $418K as of Q2 2026.
  • Principal Securities sold 1,356 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $409K.
  • Alnylam Pharmaceuticals made up 0.01% of Principal Securities's portfolio in Q2 2026, its #1161 holding.
  • Principal Securities first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Principal Securities's Alnylam Pharmaceuticals position peaked at $1.11M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.